{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T17:39:52Z","timestamp":1788716392200,"version":"build-2803163510"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norwegian Research Council","doi-asserted-by":"publisher","award":["220622\/H10"],"award-info":[{"award-number":["220622\/H10"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"South-Eastern Norway Regional Health Authority","doi-asserted-by":"publisher","award":["2011068"],"award-info":[{"award-number":["2011068"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Data on renal safety of tenofovir disoproxil fumarate (TDF) treatment among individuals with chronic hepatitis B (CHB) are inconsistent. The current study aimed to assess the effect of long-term TDF treatment on renal outcomes in adult patients with CHB.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>From a CHB cohort in Ethiopia, we included 233 patients treated with TDF and 126 untreated controls. Levels of creatinine and creatinine clearance over time were described in patients with and without TDF treatment. Linear mixed effects models with a treatment \u00d7 time interaction were used to investigate the effect of TDF on creatinine and creatinine clearance. In treated patients only, change in creatinine and creatinine clearance was estimated separately in the first year as compared with subsequent years via linear mixed effects models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Median follow-up in the treated group was 51 months (IQR, 27\u201372), and 75% of patients were male (median age, 33 years; IQR, 26\u201340). Median follow-up in the untreated group was 69 months (IQR, 66\u201372), and 48% of participants were male (median age, 33 years; IQR, 27\u201341). We found no change in creatinine over time in TDF-treated patients as compared with a slight increase in untreated patients (P interaction = .003). There was a decrease in creatinine clearance over time in both groups, which was stronger in patients without TDF treatment (P interaction = .007). In TDF-treated patients, changes in creatinine and creatinine clearance occurred mainly within the first 12 months after treatment initiation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study showed no evidence of long-term renal toxicity of TDF treatment in patients with CHB.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofad404","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T19:42:07Z","timestamp":1691437327000},"source":"Crossref","is-referenced-by-count":4,"title":["Renal Safety of Long-term Tenofovir Disoproxil Fumarate Treatment in Patients With Chronic Hepatitis B"],"prefix":"10.1093","volume":"10","author":[{"given":"Gezahegn M","family":"Woldemedihn","sequence":"first","affiliation":[{"name":"Department of Statistics, Hawassa University , Hawassa , Ethiopia"},{"name":"Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital , Oslo , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Aberra","sequence":"additional","affiliation":[{"name":"Medical Department, St Paul's Hospital Millennium Medical College , Addis Ababa , Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailemichael","family":"Desalegn","sequence":"additional","affiliation":[{"name":"Medical Department, St Paul's Hospital Millennium Medical College , Addis Ababa , Ethiopia"},{"name":"Department of Infectious Diseases, Vestfold Hospital Trust , T\u00f8nsberg , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nega","family":"Berhe","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Vestfold Hospital Trust , T\u00f8nsberg , Norway"},{"name":"Regional Centre for Imported and Tropical Diseases, Oslo University Hospital\u2013Ullev\u00e5l , Oslo , Norway"},{"name":"Aklilu Lemma Institute of Pathobiology, Addis Ababa University , Addis Ababa , Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denekew Bitew","family":"Belay","sequence":"additional","affiliation":[{"name":"Department of Statistics, Bahir Dar University , Bahir Dar , Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina S","family":"Rueegg","sequence":"additional","affiliation":[{"name":"Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital , Oslo , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5966-7166","authenticated-orcid":false,"given":"Asgeir","family":"Johannessen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Vestfold Hospital Trust , T\u00f8nsberg , Norway"},{"name":"Regional Centre for Imported and Tropical Diseases, Oslo University Hospital\u2013Ullev\u00e5l , Oslo , Norway"},{"name":"Institute of Clinical Medicine, University of Oslo , Oslo , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,7]]},"reference":[{"key":"2023082214160026500_ofad404-B1","volume-title":"Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection","author":"World Health Organization","year":"2015"},{"key":"2023082214160026500_ofad404-B2","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013","volume":"388","author":"Stanaway","year":"2016","journal-title":"Lancet"},{"key":"2023082214160026500_ofad404-B3","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1002\/cncr.29537","article-title":"Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B","volume":"121","author":"Kim","year":"2015","journal-title":"Cancer"},{"key":"2023082214160026500_ofad404-B4","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"2023082214160026500_ofad404-B5","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1086\/378068","article-title":"Tenofovir disoproxil fumarate","volume":"37","author":"Gallant","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2023082214160026500_ofad404-B6","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2165\/00003088-200443090-00003","article-title":"Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics","volume":"43","author":"Kearney","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"2023082214160026500_ofad404-B7","first-page":"372","article-title":"Clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"2023082214160026500_ofad404-B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"2023082214160026500_ofad404-B9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD Guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"2023082214160026500_ofad404-B10","doi-asserted-by":"crossref","first-page":"e9756","DOI":"10.1097\/MD.0000000000009756","article-title":"Effect of tenofovir on renal function in patients with chronic hepatitis B","volume":"97","author":"Jung","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2023082214160026500_ofad404-B11","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/jvh.13656","article-title":"Long-term renal safety between patients with chronic hepatitis B receiving tenofovir vs entecavir therapy: a multicenter study","volume":"29","author":"Chon","year":"2022","journal-title":"J Viral Hepat"},{"key":"2023082214160026500_ofad404-B12","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/jvh.13222","article-title":"An observational study on long-term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate","volume":"27","author":"Lim","year":"2020","journal-title":"J Viral Hepat"},{"key":"2023082214160026500_ofad404-B13","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1681\/ASN.2012080857","article-title":"Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?","volume":"24","author":"Tourret","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2023082214160026500_ofad404-B14","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.3748\/wjg.v25.i23.2961","article-title":"Comparison of renal safety of tenofovir and entecavir in patients with chronic hepatitis B: systematic review with meta-analysis","volume":"25","author":"Lee","year":"2019","journal-title":"World J Gastroenterol"},{"key":"2023082214160026500_ofad404-B15","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1086\/524061","article-title":"Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy","volume":"197","author":"Goicoechea","year":"2008","journal-title":"J Infect Dis"},{"key":"2023082214160026500_ofad404-B16","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/QAD.0000000000000628","article-title":"Nonalbumin proteinuria predominates in biopsy-proven tenofovir nephrotoxicity","volume":"29","author":"Sise","year":"2015","journal-title":"AIDS"},{"key":"2023082214160026500_ofad404-B17","volume-title":"Global progress report on HIV, viral hepatitis and sexually transmitted infections","author":"World Health Organization","year":"2021"},{"key":"2023082214160026500_ofad404-B18","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s12916-018-1229-x","article-title":"Treatment of chronic hepatitis B in sub-Saharan Africa: 1-year results of a pilot program in Ethiopia","volume":"16","author":"Desalegn","year":"2018","journal-title":"BMC Med"},{"key":"2023082214160026500_ofad404-B19","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1186\/s12879-017-2549-8","article-title":"Early experiences from one of the first treatment programs for chronic hepatitis B in sub-Saharan Africa","volume":"17","author":"Aberra","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2023082214160026500_ofad404-B20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"2023082214160026500_ofad404-B21","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10620-014-3486-7","article-title":"Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection","volume":"60","author":"Buti","year":"2015","journal-title":"Dig Dis Sci"},{"key":"2023082214160026500_ofad404-B22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-021-06226-0","article-title":"Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs untreated: a retrospective longitudinal UK cohort study","volume":"21","author":"Wang","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2023082214160026500_ofad404-B23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ijid.2022.09.021","article-title":"Comparison of renal safety and bone mineral density of tenofovir and entecavir in patients with chronic hepatitis B: a systematic review and meta-analysis","volume":"124","author":"Yang","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2023082214160026500_ofad404-B24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s12072-021-10271-x","article-title":"Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study","volume":"16","author":"Mak","year":"2022","journal-title":"Hepatol Int"},{"key":"2023082214160026500_ofad404-B25","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1111\/jvh.13603","article-title":"Evaluating the renal safety of tenofovir disoproxil fumarate in hepatitis B patients without chronic kidney disease","volume":"28","author":"Tsai","year":"2021","journal-title":"J Viral Hepat"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofad404\/51049664\/ofad404.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/8\/ofad404\/51218290\/ofad404.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/8\/ofad404\/51218290\/ofad404.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T15:57:37Z","timestamp":1692719857000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofad404\/7238397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofad404","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2023,8,1]]},"article-number":"ofad404"}}